
A human zzso zzso zzso directed against bacterial zzso was administered to 15 patients with incurable zzso zzso No adverse effects were noted following single intravenous infusions of zzso to 100 zzso zzso were evaluated in nine patients receiving 10 zzso zzso zzso zzso 25 zzso zzso zzso zzso and 100 zzso zzso zzso zzso Seven of these patients had initial peak serum zzso greater than zzso of predicted values with plasma disappearance zzso fitting a zzso system and a plasma zzso of zzso h zzso of zzso zzso The peak serum zzso and area under the curve values were zzso to the dose of zzso zzso One patient had a zzso state with low levels of serum zzso and zzso He achieved zzso of the predicted value for peak serum concentration of zzso with a plasma zzso of zzso zzso A second patient had zzso serum zzso for only 15 zzso following infusion without an adequate technical or zzso zzso We were unable to demonstrate zzso to zzso in zzso from these nine patients either prior to therapy or during 28 days zzso using a zzso zzso zzso This study suggests that zzso human zzso zzso administration is well tolerated by zzso Phase I trials will need to be carried out to characterize further the zzso and toxicity of zzso in patients with zzso zzso 

